Company Description
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States.
Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia.
Benitec Biopharma Inc. is headquartered in Hayward, California.
| Country | United States |
| Founded | 1995 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Jerel Banks |
Contact Details
Address: 3940 Trust Way Hayward, California 94545 United States | |
| Phone | 510 780 0819 |
| Website | benitec.com |
Stock Details
| Ticker Symbol | BNTC |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001808898 |
| CUSIP Number | 08205P209 |
| ISIN Number | US08205P2092 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sophie Mukadam | Chief Operating Officer |
| Dr. Michael Graham | Head of Discovery and Founding Scientist |
| Dr. Claudia Kloth Ph.D. | Senior Vice President of Manufacturing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | 8-K | Current Report |
| Oct 20, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 20, 2026 | DEF 14A | Other definitive proxy statements |
| Oct 5, 2026 | 8-K | Current Report |
| Sep 30, 2026 | 8-K | Current Report |
| Sep 24, 2026 | 8-K | Current Report |
| Sep 21, 2026 | EFFECT | Notice of Effectiveness |
| Sep 14, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Sep 14, 2026 | 10-K | Annual Report |
| Sep 14, 2026 | 8-K | Current Report |